
|Articles|August 13, 2008
FDA warns of adverse reactions to naltrexone
The FDA said patients should monitor the injection site.
Advertisement
The Food and Drug Administration is
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Retatrutide Delivers Weight Loss, A1C Improvements in Additional Trials
2
FDA Approves First Fixed-Dose OTC of Acetaminophen and Naproxen
3
FDA Approves First-in-Class Centanafadine for Treatment of ADHD
4
Pharmacies Successfully Scale Paid SDOH Services Through Medicaid
5

























